Cargando…

Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial

BACKGROUND: The presence of disseminated tumor cells (DTC) in bone marrow (BM) of breast cancer patients is associated with reduced clinical outcome. Bisphosphonate treatment was shown to eradicate DTC from BM in several studies. This controlled randomized open-label multi-center study aimed to inve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Banys, Malgorzata, Solomayer, Erich-Franz, Gebauer, Gerhard, Janni, Wolfgang, Krawczyk, Natalia, Lueck, Hans-Joachim, Becker, Sven, Huober, Jens, Kraemer, Bernhard, Wackwitz, Birgit, Hirnle, Peter, Wallwiener, Diethelm, Fehm, Tanja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015285/ https://www.ncbi.nlm.nih.gov/pubmed/24128322 http://dx.doi.org/10.1186/1471-2407-13-480

Ejemplares similares

ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients
por: Fehm, Tanja, et al.
Publicado: (2008)

Presence of apoptotic and nonapoptotic disseminated tumor cells reflects the response to neoadjuvant systemic therapy in breast cancer
por: Fehm, Tanja, et al.
Publicado: (2006)

Circulating and Disseminated Tumor Cells in Breast Carcinoma: Report from the Consensus Conference on Tumor Cell Dissemination during the 39th Annual Meeting of the German Society of Senology, Berlin, 27 June 2019
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2019)

Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells
por: Fehm, Tanja, et al.
Publicado: (2009)

Circulating and Disseminated Tumour Cells in Breast Carcinoma: Report from the Consensus Conference on Tumour Cell Dissemination during the 38th Annual Meeting of the German Society of Senology, Berlin, 14 June 2018
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2019)

The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy
por: Hartkopf, Andreas Daniel, et al.
Publicado: (2013)

Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay
por: Fehm, Tanja, et al.
Publicado: (2012)

The Role and Clinical Relevance of Disseminated Tumor Cells in Breast Cancer
por: Banys, Malgorzata, et al.
Publicado: (2014)

Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
por: Fehm, Tanja, et al.
Publicado: (2007)

Prognostic relevance of induced and spontaneous apoptosis of disseminated tumor cells in primary breast cancer patients
por: Krawczyk, Natalia, et al.
Publicado: (2014)

State of the art of neoadjuvant chemotherapy in breast cancer: rationale, results and recent developments
por: Honig, Arnd, et al.
Publicado: (2005)

Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients
por: Aktas, Bahriye, et al.
Publicado: (2016)

Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2017)

The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2019)

Potential Role of Circulating Tumor Cell Detection and Monitoring in Breast Cancer: A Review of Current Evidence
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2016)

Liquid Biopsy in Breast Cancer
por: Banys-Paluchowski, Maggie, et al.
Publicado: (2020)

The PACOVAR-trial: A phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer
por: Eichbaum, Michael, et al.
Publicado: (2011)

Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2018)

Clinical relevance of circulating tumor cells in ovarian, fallopian tube and peritoneal cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2020)

Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells
por: Kasimir-Bauer, Sabine, et al.
Publicado: (2012)

Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: A phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy
por: Krainick-Strobel, Ute E, et al.
Publicado: (2008)

Comment on the LACC Trial Investigating Early-stage Cervical Cancer by the Uterus Commission of the Study Group for Gynecologic Oncology (AGO) and the Study Group for Gynecologic Endoscopy (AGE) of the German Society for Gynecology and Obstetrics (DGGG)
por: Hillemanns, Peter, et al.
Publicado: (2018)

Simultaneous Detection of Disseminated and Circulating Tumor Cells in Primary Breast Cancer Patients
por: Hartkopf, Andreas D., et al.
Publicado: (2016)

Selective microdochectomy after ductoscopic wire marking in women with pathological nipple discharge
por: Hahn, M, et al.
Publicado: (2009)

Circulating tumour cells in breast cancer
por: Krawczyk, Natalia, et al.
Publicado: (2013)

Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study
por: Müller, Volkmar, et al.
Publicado: (2012)

Expression of Stem Cell and Epithelial-Mesenchymal Transition Markers in Circulating Tumor Cells of Breast Cancer Patients
por: Krawczyk, Natalia, et al.
Publicado: (2014)

Update Breast Cancer 2017 – Implementation of Novel Therapies
por: Lux, Michael P., et al.
Publicado: (2017)

Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer
por: Müller, Volkmar, et al.
Publicado: (2011)

Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program
por: Müller, V., et al.
Publicado: (2021)

Post-Neoadjuvant Treatment in HER2-Positive Breast Cancer: Escalation and De-Escalation Strategies
por: Krawczyk, Natalia, et al.
Publicado: (2022)

Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1
por: Neubauer, Hans, et al.
Publicado: (2008)

Correction: Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1
por: Neubauer, Hans, et al.
Publicado: (2009)

Determination of the androgen receptor status of circulating tumour cells in metastatic breast cancer patients
por: Krawczyk, Natalia, et al.
Publicado: (2019)

Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany
por: Huebner, Hanna, et al.
Publicado: (2020)

Multidisciplinary breast centres in Germany: a review and update of quality assurance through benchmarking and certification
por: Wallwiener, Markus, et al.
Publicado: (2012)

Classifying breast cancer surgery: a novel, complexity-based system for oncological, oncoplastic and reconstructive procedures, and proof of principle by analysis of 1225 operations in 1166 patients
por: Hoffmann, Jürgen, et al.
Publicado: (2009)

Return of individual genomic research results within the PRAEGNANT multicenter registry study
por: Huebner, Hanna, et al.
Publicado: (2022)

Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
por: Lux, Michael P., et al.
Publicado: (2018)

Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
por: Michel, Laura L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_reso17ndejb3nlotjpjl9qurd9